Metastatic Castration-Resistant Prostate Cancer: Updates to VISION Trial Data

Scott Tagawa, MD, MS, FACP, comments on treatment and management strategies in metastatic castration-resistant prostate cancer (CRPC), and reviews recent data on the VISION trial of Lu 177 vipivotide tetraxetan.